MASH

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver health benefits independent of this mechanism.

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle modifications.

Inclusion of female and Hispanic/Latino patients has increased over time, but most trials of metabolic dysfunction-associated steatohepatitis (MASH) still take place in high-income countries and have majority-White patient populations.

The invasive nature of lipid biopsies has lead researchers to dedicate more efforts to unveiling noninvasive diagnostic methods for metabolic dysfunction–associated steatohepatitis (MASH).

Rising rates of metabolic dysfunction–associated steatohepatitis indicate a need for public health interventions.

At 2 years, participants in the compensated MASH cirrhosis treatment arm of the MAESTRO-NAFLD-1 trial experienced a statistically significant 6.7 kPa reduction in liver stiffness from baseline.

Preliminary topline week 96 results showed statistically significant reversal of metabolic dysfunction–associated steatohepatitis (MASH)–compensated cirrhosis with efruxifermin in complete and intent-to-treat analyses.

Emerging evidence suggests that fibroblast growth factor 21 (FGF21) could play a future part in the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

As a growing number of young adults with primary liver cancer (PLC) related to metabolic dysfunction–associated steatohepatitis (MASH) age, developing coherent strategies to combat the metabolic disease epidemic is critical.

The investigators believe their decades-spanning analysis underscores the need to address access barriers to anti-obesity therapeutics.

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 receptor agonist (GLP-1RA) could see their liver health improve with the addition of efruxifermin.

Peptidomics offered new diagnostic insights into the underlying processes of metabolic dyfunction-associated steatotic liver disease (MASLD).

The global burden of liver cancer is rising, and public health efforts for prevention, vaccination, and treatment to address underlying etiologies are needed, according to research presented at ASCO 2024.

The first medication for the treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis received accelerated approval. Previously, the only treatment available to patients was implementing lifestyle changes aimed at weight reduction.

There are no FDA-approved therapies for nonalcoholic steatohepatitis (NASH), but there are many being developed. Resmetirom and obeticholic acid are both being reviewed by the FDA with decisions expected in 2023.

A recent study aims to improve evaluation of fatty liver in ultrasound scans to increase hepatology referrals and predict significant liver fibrosis.